FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021415488> ?p ?o ?g. }

• W2021415488 endingPage "489" @default.
• W2021415488 startingPage "482" @default.
• W2021415488 abstract "Abstract. Purpose: Choroidal neovascularization (CNV) accounts for 85–90% of severe visual impairment in age‐related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a major factor mediating angiogenesis, and VEGF inhibitors have become a new treatment modality. In this prospective study, we used bevacizumab (Avastin ® ), a recombinant monoclonal antibody to VEGF, to treat neovascular AMD. Methods: The case material comprised 36 subjects (26 females, 10 males) aged 65–88 years with subfoveal neovascular AMD with all subtypes of CNV. There were two categories of patients: category I, long‐standing CNV (12 months or more), preoperative visual acuity (VA) 0.16 (mean); category II, CNV (duration <12 months), preoperative VA 0.25 (mean). Evaluation protocol included the Early Treatment Diabetic Retinopathy Study (ETDRS) VA, clinical ophthalmological examination, fluorescein angiography and optical coherence tomography (OCT). Intravitreal injections of bevacizumab (Avastin ® ) (IVB), 1.25 mg (0.05 ml), were given under an operating microscope and aseptic conditions in a theatre for surgery with intervals of 4 or 6 weeks during the first 3 months and subsequently according to clinical assessment. The follow‐up was 6 months in all cases. Results: At 6 months, mean VA had improved by 4.6 ETDRS letters in the entire case material ( P = 0.001), by 3.9 letters in category I (duration 12 months or more) and by 6.0 letters in category II (duration <12 months). A total of 148 IVB (mean 4.1 injections/eye) were delivered during 6 months, the first 3 months comprising 3.1 IVB (mean) and the last 3 months 1.0 IVB (mean). No eyes suffered visual decline of 15 ETDRS letters. Fluorescein angiograms displayed stabilization or regression of CNV activity; OCT showed resorption of intraretinal oedema and subretinal fluid. No severe complications occurred but recurrence was common, and repeated IVBs were necessary in most cases during the 6‐month period. Conclusion: When addressing the issue of frequency of IBV, we observed that 6‐week intervals were sufficient because VA and CNV lesions generally stabilized at 4 weeks. The gain in VA was promising in eyes with <12 months CNV duration. Even in eyes with a longer CNV duration, a slight visual improvement was observed when retinal oedema resorbed, although subretinal fibrosis and general cellular damage certainly limited recovery." @default.
• W2021415488 created "2016-06-24" @default.
• W2021415488 creator A5004809324 @default.
• W2021415488 creator A5018697149 @default.
• W2021415488 creator A5062354919 @default.
• W2021415488 creator A5069676697 @default.
• W2021415488 date "2008-07-22" @default.
• W2021415488 modified "2023-10-18" @default.
• W2021415488 title "A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration of different durations" @default.
• W2021415488 cites W1802218256 @default.
• W2021415488 cites W1965259073 @default.
• W2021415488 cites W1968609549 @default.
• W2021415488 cites W1981608508 @default.
• W2021415488 cites W1988233478 @default.
• W2021415488 cites W1995708259 @default.
• W2021415488 cites W1999611557 @default.
• W2021415488 cites W2000292756 @default.
• W2021415488 cites W2000836065 @default.
• W2021415488 cites W2007917457 @default.
• W2021415488 cites W2015843817 @default.
• W2021415488 cites W2020050260 @default.
• W2021415488 cites W2023523208 @default.
• W2021415488 cites W2026626516 @default.
• W2021415488 cites W2033245558 @default.
• W2021415488 cites W2039936409 @default.
• W2021415488 cites W2058775052 @default.
• W2021415488 cites W2085366579 @default.
• W2021415488 cites W2085712747 @default.
• W2021415488 cites W2096735172 @default.
• W2021415488 cites W2123232376 @default.
• W2021415488 cites W2153632706 @default.
• W2021415488 cites W2157769714 @default.
• W2021415488 cites W2233259956 @default.
• W2021415488 doi "https://doi.org/10.1111/j.1600-0420.2007.01113.x" @default.
• W2021415488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18162062" @default.
• W2021415488 hasPublicationYear "2008" @default.
• W2021415488 type Work @default.
• W2021415488 sameAs 2021415488 @default.
• W2021415488 citedByCount "88" @default.
• W2021415488 countsByYear W20214154882012 @default.
• W2021415488 countsByYear W20214154882013 @default.
• W2021415488 countsByYear W20214154882014 @default.
• W2021415488 countsByYear W20214154882015 @default.
• W2021415488 countsByYear W20214154882016 @default.
• W2021415488 countsByYear W20214154882017 @default.
• W2021415488 countsByYear W20214154882018 @default.
• W2021415488 countsByYear W20214154882019 @default.
• W2021415488 countsByYear W20214154882020 @default.
• W2021415488 countsByYear W20214154882021 @default.
• W2021415488 countsByYear W20214154882022 @default.
• W2021415488 countsByYear W20214154882023 @default.
• W2021415488 crossrefType "journal-article" @default.
• W2021415488 hasAuthorship W2021415488A5004809324 @default.
• W2021415488 hasAuthorship W2021415488A5018697149 @default.
• W2021415488 hasAuthorship W2021415488A5062354919 @default.
• W2021415488 hasAuthorship W2021415488A5069676697 @default.
• W2021415488 hasConcept C118487528 @default.
• W2021415488 hasConcept C126322002 @default.
• W2021415488 hasConcept C134018914 @default.
• W2021415488 hasConcept C141071460 @default.
• W2021415488 hasConcept C188816634 @default.
• W2021415488 hasConcept C2776403814 @default.
• W2021415488 hasConcept C2776694085 @default.
• W2021415488 hasConcept C2777802072 @default.
• W2021415488 hasConcept C2778257484 @default.
• W2021415488 hasConcept C2778271429 @default.
• W2021415488 hasConcept C2779829184 @default.
• W2021415488 hasConcept C2780248432 @default.
• W2021415488 hasConcept C2780394083 @default.
• W2021415488 hasConcept C2781359195 @default.
• W2021415488 hasConcept C555293320 @default.
• W2021415488 hasConcept C71924100 @default.
• W2021415488 hasConceptScore W2021415488C118487528 @default.
• W2021415488 hasConceptScore W2021415488C126322002 @default.
• W2021415488 hasConceptScore W2021415488C134018914 @default.
• W2021415488 hasConceptScore W2021415488C141071460 @default.
• W2021415488 hasConceptScore W2021415488C188816634 @default.
• W2021415488 hasConceptScore W2021415488C2776403814 @default.
• W2021415488 hasConceptScore W2021415488C2776694085 @default.
• W2021415488 hasConceptScore W2021415488C2777802072 @default.
• W2021415488 hasConceptScore W2021415488C2778257484 @default.
• W2021415488 hasConceptScore W2021415488C2778271429 @default.
• W2021415488 hasConceptScore W2021415488C2779829184 @default.
• W2021415488 hasConceptScore W2021415488C2780248432 @default.
• W2021415488 hasConceptScore W2021415488C2780394083 @default.
• W2021415488 hasConceptScore W2021415488C2781359195 @default.
• W2021415488 hasConceptScore W2021415488C555293320 @default.
• W2021415488 hasConceptScore W2021415488C71924100 @default.
• W2021415488 hasIssue "5" @default.
• W2021415488 hasLocation W20214154881 @default.
• W2021415488 hasLocation W20214154882 @default.
• W2021415488 hasOpenAccess W2021415488 @default.
• W2021415488 hasPrimaryLocation W20214154881 @default.
• W2021415488 hasRelatedWork W2076711558 @default.
• W2021415488 hasRelatedWork W2616362931 @default.
• W2021415488 hasRelatedWork W2991715136 @default.
• W2021415488 hasRelatedWork W2991939470 @default.
• W2021415488 hasRelatedWork W2993662524 @default.

• next